Abstract
The ability of a potential human anti-cancer therapeutic agent to inhibit the growth of xenografted tumors in nude mice has been an established and accepted testing method for several decades. The current report shows that a single, low-level intravenous dose of [32P]ATP significantly inhibits the growth of established xenografted tumors in nude mice. This inhibitory effect becomes appreciable very rapidly, within only five days post-injection and the low dose demonstrates little or no toxicity in the mice. Surprisingly, a narrow dose window of optimum effectiveness is seen, whereby either decreasing or increasing the [32P]ATP dose results in far less growth inhibition. Thus, the intravenous systemic injection of [32P]ATP may represent a simple, potent method to target and inhibit primary human tumors and malignant lesions.
Original language | English (US) |
---|---|
Pages (from-to) | 461-466 |
Number of pages | 6 |
Journal | Oncotarget |
Volume | 2 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2011 |
Keywords
- Inhibition
- Nude mice
- Xenografts
ASJC Scopus subject areas
- Oncology